Navigation Links
Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program
Date:8/29/2011

MISSISSAUGA, Ontario, Aug. 29, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (the "Company" or "Valeant") announced today that its Board of Directors has approved an increase of $300 million under its previously announced securities repurchase program (the "Securities Repurchase Program").  Under the Securities Repurchase Program, Valeant may now repurchase up to $1.8 billion of its convertible notes, senior notes, common shares and/or other notes or shares that may be issued prior to the completion of the program. As part of this Securities Repurchase Program, Valeant also recently announced that it had filed a Notice of Intention to make a normal course issuer bid to repurchase up to 1,000,000 of its common shares through the facilities of the Toronto Stock Exchange ("TSX").

The Securities Repurchase Program will terminate on November 7, 2011 or at such time as Valeant completes its purchases.  To date, the Company has purchased 14,969,599 of its common shares for aggregate consideration of $590.6 million and a total of $302.5 million principal amount of its 5.375% Convertible Notes for aggregate consideration of $806.3 million. The amount of securities to be purchased and the timing of purchases under the Securities Repurchase Program may be subject to various factors, which may include the price of the securities, general market conditions, corporate and regulatory requirements, alternate investment opportunities and restrictions under the Company's financing agreements. The securities to be repurchased will be funded using Valeant's cash resources.

Valeant believes that the proposed purchases are in the best interests of the Company and are a desirable use of corporate funds. The Securities Repurchase Program may be modified, suspended or terminated at any time without prior notice.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) i
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Announces Pricing of Senior Notes
9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
(Date:12/22/2014)... and STOCKHOLM , Dec. ... (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that ... of the European Medicines Agency (EMA) has adopted a ... histolyticum) for the treatment of adult men with Peyronie,s ... at least 30 degrees at the start of therapy. ...
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... URINOZINC® Plus with Beta-Sitosterol, the latest addition to the ... at select Walmart stores. (Photo:   http://photos.prnewswire.com/prnh/20110627/CG25869 ... with a US Patent for helping alleviate symptoms associated ... been sold. The main cause of ...
... BioDrain Medical, Inc. (OTCBB: BIOR, OTCQB: BIOR), producer ... fluid disposal, today announced that it has placed two ... surgical facilities in Minnesota.  The Streamway System has received ... sites. Healthcare personnel trained in the use ...
Cached Medicine Technology:Walmart Stores Now Offer URINOZINC® Plus With Beta-Sitosterol 2BioDrain Streamway® System Receives Positive Evaluations on Two Additional Units 2BioDrain Streamway® System Receives Positive Evaluations on Two Additional Units 3
(Date:12/22/2014)... 2014 The Bob Woodruff Foundation ... invested more than $5 million in programs and ... their families. , This includes $1.3 million in ... helping with: veteran entrepreneurship; community impact; vocational training; ... severely injured veterans. , “The needs of those ...
(Date:12/22/2014)... Naples, Florida (PRWEB) December 22, 2014 ... this holiday season, the gift of health and vitality. ... is offering its three top-selling anti-aging formulas in special ... with free rush delivery. , Each bottle contains ... digestion, areas that don't work as well as we ...
(Date:12/22/2014)... 22, 2014 Xarelto Lawsuit News ... of judges has granted a request to centralize pending ... District Court, Eastern District of Louisiana. The U.S. Judicial ... December 12 to transfer over 50 Xarelto cases–21 lawsuits ... the Louisiana court for consolidation under U.S. District Judge ...
(Date:12/22/2014)... St. Petersburg, FL (PRWEB) December 22, 2014 ... needed. Sublime Beauty® has a fast and easy solution that ... online gift cards can be purchased from from $25 up ... ®. "We offer 100% customer satisfaction and a wide array ... cards have no fees and no expiration dates. , ...
(Date:12/22/2014)... DC (PRWEB) December 22, 2014 ... its year-long, professional development programs this month. Faculty ... which focuses on nurse educators fast-tracked for administrative ... the Leadership Development Program for Simulation Educators, featuring ... specialized area of nursing education. , Twenty ...
Breaking Medicine News(10 mins):Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3
... exercise, can keep lung tumors at bay, one study found ... environment can affect your risk for cancer, so can everyday ... new research shows. , The findings were to be presented ... conference on cancer prevention. , One study found that people ...
... Data on Perifosine in the Treatment of Patients ... on Saturday, December 8th at 5:30pm, NEW ... KERX ) today announced that abstracts related to ... poster sessions,scheduled to take place at the upcoming ...
... Symptoms Among Frequent Complaints in Expectant,Mothers, ... from,the American College of Gastroenterology have released ... challenges of caring,for women with chronic digestive ... to pregnancy., "Given the large number ...
... Caring, Inc. has been,awarded the Maryland Association ... completing the Standards for Excellence,certification program. Hospice ... examining its compliance with the Maryland Nonprofits ... for the Nonprofit Sector., Standards for ...
... HARBOR, N.Y. In recent years, significant progress ... authoritative new book published by Cold Spring Harbor Laboratory ... advances on the molecular basis of aging, such as ... relationship between diet and aging. They also discuss ...
... Universitys School of Dentistry and Oral Health welcomes the Queensland ... a measure endorsed by all major international and Australian ... , The decision will ensure that 80 ... two years, and more than 90 per cent of the ...
Cached Medicine News:Health News:Everyday Choices Can Influence Cancer Risk 2Health News:Everyday Choices Can Influence Cancer Risk 3Health News:Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia 2Health News:Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia 3Health News:Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia 4Health News:Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia 5Health News:American College of Gastroenterology Offers Updated Clinical Guidance for Managing Pregnant Patients 2Health News:American College of Gastroenterology Offers Updated Clinical Guidance for Managing Pregnant Patients 3Health News:Hospice Caring, Inc. Earns Seal of Excellence and Elects New Board Member 2Health News:New book presents comprehensive survey of research into the molecular basis of aging 2Health News:Fluoridated water for Queensland ... at last 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: